SCHEMBL20134987

SCHEMBL20134987

COCC(C)(C)C(=O)c1ccc(C(=O)OC)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.50
CA2 P00918 5/20 0.50
MAPT P10636 3/20 0.50
TDP1 Q9NUW8 1/20 0.50
CA12 O43570 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
LOXL2 Q9Y4K0 1/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TSHR P16473 1/20 0.47
ALDH1A1 P00352 1/20 0.46
NOTUM Q6P988 1/20 0.45
CYP4A11 Q02928 2/20 0.45
RAB9A P51151 2/20 0.44
HPGD P15428 1/20 0.44
CYP4F2 P78329 1/20 0.44
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135545 0.84 CA1 (0.47) CA1CA2CA12CA7CA9
SCHEMBL757100 0.81 CES1 (0.50) MAPTTDP1MEN1KMT2ATSHR
SCHEMBL6919651 0.79 CA1 (0.59) CA1CA2MAPTTDP1CA12
SCHEMBL20135405 0.77 CA1 (0.57) CA1CA2MAPTTDP1CA12
SCHEMBL23600 0.76 CA1 (0.80) CA1CA2MAPTTDP1CA12
SCHEMBL20135443 0.76 CA1 (0.55) CA1CA2MAPTTDP1CA12
SCHEMBL28993944 0.76 CA1 (0.80) CA1CA2MAPTTDP1CA12
SCHEMBL14217435 0.75 MAPT (0.50) CA1CA2MAPTTDP1CA12
SCHEMBL26569822 0.74 CA1 (0.53) CA1CA2MAPTTDP1CA12
SCHEMBL21164588 0.73 NAMPT (0.56) CA1CA2MAPTTDP1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 CA1 1423/4885CA2 579/4885MAPT 4505/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 CA1 1245/4885CA2 470/4885MAPT 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.